Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Regulation Of The Level And Glycosylation State Of Plasminogen Activator Inhibitor Type 2 During Human Keratinocyte Differentiation.
Y. Wang, P. Jensen
Published 1998 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Plasminogen activator inhibitor type 2 (PAI-2) is an unusual member of the serine proteinase inhibitor (serpin) family which has been implicated in the protection of cells from programmed cell death. Human epidermal keratinocytes synthesize large amounts of PAI-2 in two active forms: glycosylated and non-glycosylated. Calcium (Ca2+), a well-known inducer of numerous aspects of keratinocyte terminal differentiation, increases the steady-state levels of PAI-2 mRNA and protein. As the cultures become more differentiated due to longer incubation with Ca2+, the glycosylated form is preferentially elevated. Surprisingly, glycosylated as well as non-glycosylated PAI-2 remains predominantly cell-associated, in a trypsin-inaccessible form and thus most likely inside the cell. Tumor necrosis factor-alpha (TNF-alpha), an inflammatory mediator that induces some markers of keratinocyte differentiation, also increases PAI-2 mRNA and protein levels. Experiments using cultures in which protein kinase C has been downregulated suggest that Ca2+, but not TNF-alpha, acts at least partially through one or more isozymes of this kinase for induction of PAI-2. This is consistent with the finding that the effect of simultaneous addition of Ca2+ plus TNF-alpha is at least additive, compared with addition of either stimulant alone. These data demonstrate that the keratinocyte maintains multiple regulatory pathways for control of PAI-2 expression, at least one of which is related to terminal differentiation.
This paper references
Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2.
D. Belin (1989)
Modulation of growth and differentiation in normal human keratinocytes by transforming growth factor‐β
K. Matsumoto (1990)
Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.
J. Dickinson (1995)
Apoptosis in human skin development: Morphogenesis, periderm, and stem cells
R. Polakowska (1994)
Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells.
W. D. Schleuning (1987)
Localization of tumour necrosis factor‐alpha (TNF‐α) and its receptors in normal and psoriatic skin: epidermal cells express the 55‐kD but not the 75‐kD TNF receptor
M. Kristensen (1993)
Clonal growth of normal human epidermal keratinocytes in a defined medium
M. Tsao (1982)
Apoptosis: the skin from a new perspective.
R. Polakowska (1994)
The ovalbumin family of serpin proteins
E. Remold-O'Donnell (1993)
S100A11, S100A10, Annexin I, Desmosomal Proteins, Small Proline-rich Proteins, Plasminogen Activator Inhibitor-2, and Involucrin Are Components of the Cornified Envelope of Cultured Human Epidermal Keratinocytes*
N. Robinson (1997)
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells
C. Genton (1987)
Plasminogen activator inhibitor type 2: an intracellular keratinocyte differentiation product that is incorporated into the cornified envelope.
P. Jensen (1995)
Coordinate changes in gene expression which mark the spinous to granular cell transition in epidermis are regulated by protein kinase C
A. Dlugosz (1993)
Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light
A. Köck (1990)
Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes.
S. Pillai (1989)
Plasminogen activator-specific inhibitors produced by human monocytes/macrophages
A. Wohlwend (1987)
Epidermal growth factor and insulin-like growth factor I enhance keratinocyte migration.
Y. Ando (1993)
Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures.
P. Jensen (1993)
A Novel Matrix Attachment Region DNA Binding Motif Identified Using a Random Phage Peptide Library (*)
B. Wang (1995)
Protein kinase C mediates up‐regulation of urokinase and its receptor in the migrating keratinocytes of wounded cultures, but urokinase is not required for movement across a substratum in vitro
Y. Ando (1996)
Modulation of the plasminogen activator cascade during enhanced epidermal proliferation in vivo.
P. Jensen (1996)
Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture.
S. Boyce (1983)
Programmed cell death in terminally differentiating keratinocytes: role of endogenous endonuclease.
C. McCall (1991)
Expression of plasminogen activator inhibitor 2 in the adult and embryonic mouse tissues.
Y. Kawata (1996)
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.
E. K. Kruithof (1986)
Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2.
S. Kumar (1991)
Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells.
T. Antalis (1992)
Differentiation-linked expression of the plasminogen activator inhibitor type-2 gene in the human HL-60 promyelocytic cell line.
A. Arndt (1989)
Specific protein kinase C isozymes mediate the induction of keratinocyte differentiation markers by calcium.
M. Denning (1995)
Human plasma proteinase inhibitors.
J. Travis (1983)
Induction of plasminogen activator inhibitor type 2 expression during differentiation of human K562 cells towards a macrophage phenotype.
A. Rehemtulla (1990)
Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium.
G. Shipley (1986)
This paper is referenced by
Brett Novel Consensus Motif Plasminogen Activator Inhibitor 2 via a Degradation by Interaction with the Serpin Inhibition of Retinoblastoma Protein
G. Darnell (2003)
Regulation of trespin expression by modulators of cell growth, differentiation, and apoptosis in prostatic epithelial cells.
L. Stewart (2003)
Immunobiologicals for Psoriasis: Using Targeted Immunotherapies as Pathogenic Probes in Psoriasis
G. Weinstein (2003)
Sodium dodecyl sulfate induces plasminogen activator inhibitor type 2 expression in epidermal keratinocytes in vivo and in vitro.
N. M. Chung (2001)
Plasminogen activator inhibitor type 2 in human corneal epithelium.
D. Williams (1999)
Immunopathogenesis of psoriasis
M. R. Lee (2006)
Novel immunotherapies for psoriasis: clinical research delivers new hope for patients and scientific advances.
A. Gottlieb (2004)
Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis.
Frank C Victor (2003)
Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma.
Jodi A. Lee (2011)
A Physiological Function of Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity
W. Schroder (2010)
Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2.
L. Major (2011)
Differentiating cells of murine stratified squamous epithelia constitutively express plasminogen activator inhibitor type 2 (PAI-2)
B. Risse (1998)
Transcriptome Analyses in Normal Prostate Epithelial Cells Exposed to Low-Dose Cadmium: Oncogenic and Immunomodulations Involving the Action of Tumor Necrosis Factor
Shlomo Bakshi (2008)
Evidence for intracellular cleavage of plasminogen activator inhibitor type 2 (PAI‐2) in normal epidermal keratinocytes
B. Risse (2000)
Novel immunobiologics for psoriasis
N. Ghosh (2008)
Sweating the small stuff: Glycoproteins in human sweat and their unexplored potential for microbial adhesion.
R. Peterson (2016)
Plasminogen activator inhibitor type 2 (PAI‐2) is present in normal human conjunctiva
M. Massaro-Giordano (2005)
Psoriasis and its treatment with infliximab-mediated tumor necrosis factor α blockade
L. Winterfield (2004)
Infliximab for psoriasis.
A. Gottlieb (2003)
Extracellular proteolysis and venous leg ulcer
M. Weckroth (2004)
Characterisation of SerpinB2 as a stress response modulator
Jodi A. Lee (2015)
Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif
G. Darnell (2003)
Psoriasis: a fresh look.
I. Galadari (2005)
Laura S. Winterfield (2004)
Dysregulated ΔNp63α negatively regulates the maspin promoter in keratinocytes via blocking endogenous p73 binding
K. King (2014)
Trps1 transcription factor represses phosphate-induced expression of SerpinB2 in osteogenic cells.
M. Socorro (2020)